Grants and Contracts
Congratulations to the following individuals for obtaining extramural funding from federal, state, and/or independent sources between August 1 and October 31, 2022!
NOTE: If any information has been inadvertently omitted, please contact the editor (dflock@lsuhsc.edu) and a correction will be printed in the next issue of The Pulse.
National Institutes of Health (R01)
Qinglin Yang, PhD (Pharmacology and Cardiovascular Center of Excellence)
“Energetic State and Metabolic Remodeling in Cardiac Hypertrophy and Failure”
National Institutes of Health (F32)
Sydney Vita, PhD (Physiology)
“Alcohol Exposure Exacerbates Inflammation and Anxiety-like Behavior Induced by Repeated
Mild TBI During Adolescence.”
National Institutes of Health (K99)
Marcus Weera, PhD (Physiology)
“Lateral Hypothalamas Circuits in Stress Induced Blunting of Alcohol Aversion”
National Institutes of Health (U19)
Christopher Taylor, PhD (Microbiology, Immunology, and Parasitology; Consortium/Core
PI)
“Transomics Integration of Multiomics Studies of Osteoporosis”
Cooperative agreement with Tulane University
National Institutes of Health (UM1)
Pam Kozlowski, PhD (Microbiology, Immunology, and Parasitology; Consortium PI)
“B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection”
Cooperative agreement with Emery University
Department of Veterans Affairs Office of Rural Health
Gala True, PhD (Medicine, Section of Community and Population Health)
“Preventing Firearm Suicides Among Rural Veterans by Engaging Military Caregivers”
University Collaborations
Tulane University
Traci Goodchild, PhD (Pharmacology and Cardiovascular Center of Excellence)
“Insulin-Like Growth Factor-1 and Atherosclerosis (SWINE)”
Pharmaceutical and Company Grants
Jeffrey Carter, MD (Surgery)
ATI Advanced Technology International
“Burn Training-001: Burns for Prehospital Providers Program (BPPP)”
Kyle Happel, MD (Medicine, Section of Pulmonary/Critical Care & Allergy/Immunology)
Astra Zeneca Pharmaceuticals
“A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group,
Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens
of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease
(COPD) with a History of COPD Exacerbations (TITANIA)”
Michelle Loch, MD (Medicine, Section of Hematology and Oncology)
Criterium, Inc.
“Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in
Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed”
Piotr Olejniczak, MD, PhD (Neurology)
Parexel International Corp
“A Double-Blind Randomized Placebo-controlled Multicenter Outpatient Parallel Group
Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants
12 Years of Age and Older with Epilepsy with Stereotypical Prolonged Seizures”
Frank Smart, MD (Medicine, Section of Cardiology)
Amgen, Inc.
“A Multicenter Cross-sectional Study to Characterize the Distribution of Lipoprotein
Levels in Patients with Documented History of ASCVD”
Rohan Walvekar, MD (Otolaryngology)
Cook Medical
“Development of Dissolution Agent to Treat Sialolthiasis”
Peter Winsauer, PhD (Pharmacology)
Full Spectrum Omega, Inc.
“Full Spectrum Protection Against Development of Dietary Non-Alcoholic Steatohepatitis
(NASH)”
Professional Associations
Alison Smith, MD, PhD (Surgery)
American Association for the Surgery of Trauma
Research and Education Fund Trauma Critical Care Scholarship